688289.SH
圣湘生物
SSE · Healthcare · Medical - Instruments & Supplies · CN
CNY 14.90
−5.58%Aug 26, 2026, 11:21 UTC
Sansure Biotech proposed a cash dividend of 2.65 yuan per 10 shares (tax inclusive), totaling 151 million yuan, subject to shareholder approval.
Source:Aug 26, 2026, 11:21 UTC
Sansure Biotech announced its first-half 2026 results: revenue of 834 million yuan, down 3.95% year-on-year; net profit attributable to shareholders of 98.0173 million yuan, down 39.76%; non-recurring net profit of 53.7043 million yuan, down 60.48%.
Source:Aug 18, 2026, 11:11 UTC
Sansure Biotech announced that its dengue and chikungunya virus nucleic acid detection kit received a medical device registration certificate from China's National Medical Products Administration, valid until August 16, 2031.
Source: